{"id":"lm-108-in-combination-with-toripalimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Toripalimab is a PD-1 inhibitor that releases the brakes on T-cell mediated anti-tumor immunity. LM-108's specific mechanism is not publicly detailed, but the combination is designed to provide complementary immunomodulation. This dual approach aims to overcome resistance to single-agent checkpoint inhibition in solid tumors.","oneSentence":"LM-108 combined with Toripalimab works by blocking immune checkpoints to enhance anti-tumor immunity, with LM-108 targeting a specific immune pathway while Toripalimab blocks PD-1.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:12.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05518045","phase":"PHASE1, PHASE2","title":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2022-08-26","conditions":"Advanced Solid Tumor","enrollment":392},{"nctId":"NCT07362186","phase":"PHASE3","title":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2026-04-03","conditions":"Locally Advanced or Metastatic GC and GCJ Adenocarcinoma","enrollment":400},{"nctId":"NCT06873854","phase":"PHASE2","title":"A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours","status":"NOT_YET_RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2025-03-26","conditions":"Advanced Solid Tumor","enrollment":84},{"nctId":"NCT06387628","phase":"PHASE2","title":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-10","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LM-108 in combination with Toripalimab","genericName":"LM-108 in combination with Toripalimab","companyName":"LaNova Medicines Limited","companyId":"lanova-medicines-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LM-108 combined with Toripalimab works by blocking immune checkpoints to enhance anti-tumor immunity, with LM-108 targeting a specific immune pathway while Toripalimab blocks PD-1. Used for Solid tumors (specific indications under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}